Karolinska Institutet
Browse

Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles.

Download (3.98 MB)
journal contribution
posted on 2024-10-30, 11:31 authored by Dhanu GuptaDhanu Gupta, Oscar WiklanderOscar Wiklander, André GörgensAndré Görgens, Mariana Conceição, Giulia Corso, Xiuming LiangXiuming Liang, Yiqi Seow, Sriram Balusu, Ulrika Feldin, Beklem Bostancioglu, Rim Jawad, Doste Rashid MamandDoste Rashid Mamand, Yi Xin Fiona Lee, Justin Hean, Imre Mäger, Thomas C Roberts, Manuela Gustafsson, Dara MohammadDara Mohammad, Helena SorkHelena Sork, Alexandra Backlund, Per Lundin, Antonin de Fougerolles, CI Edvard Smith, Matthew JA Wood, Roosmarijn E Vandenbroucke, Joel NordinJoel Nordin, Samir El-AndaloussiSamir El-Andaloussi
Extracellular vesicles (EVs) can be functionalized to display specific protein receptors on their surface. However, surface-display technology typically labels only a small fraction of the EV population. Here, we show that the joint display of two different therapeutically relevant protein receptors on EVs can be optimized by systematically screening EV-loading protein moieties. We used cytokine-binding domains derived from tumour necrosis factor receptor 1 (TNFR1) and interleukin-6 signal transducer (IL-6ST), which can act as decoy receptors for the pro-inflammatory cytokines tumour necrosis factor alpha (TNF-α) and IL-6, respectively. We found that the genetic engineering of EV-producing cells to express oligomerized exosomal sorting domains and the N-terminal fragment of syntenin (a cytosolic adaptor of the single transmembrane domain protein syndecan) increased the display efficiency and inhibitory activity of TNFR1 and IL-6ST and facilitated their joint display on EVs. In mouse models of systemic inflammation, neuroinflammation and intestinal inflammation, EVs displaying the cytokine decoys ameliorated the disease phenotypes with higher efficacy as compared with clinically approved biopharmaceutical agents targeting the TNF-α and IL-6 pathways.

Funding

COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values : European Commission | 681463

Release of engineered extracellular vesicles for delivery of biotherapeutics : European Research Council | 101001374

History

File version

  • Accepted manuscript

Publication status

Published

Sub type

Article

Journal

Nat Biomed Eng

ISSN

2157-846X

eISSN

2157-846X

Volume

5

Issue

9

Language

  • eng

Original self archiving date

2022-12-06

Usage metrics

    Articles

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC